Navigation Links
Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine

t to risks and uncertainties and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. The reader

should not rely on any forward-looking statement. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, in addition to the specific factors discussed in connection with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements contained in this press release. Important factors that may affect future results include, but are not limited to: market acceptance of the Company's products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company's product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre-clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and re
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/1/2015)... RUTHERFORD, N.J., May 1, 2015 Cambrex Corporation (NYSE: ... March 31, 2015. Highlights , ... and increased 27% excluding foreign currency impact, driven by Innovator ... million from $8.4 million in the first quarter of 2014. ... versus $0.04 in the first quarter last year and Adjusted ...
(Date:4/30/2015)... Calif., April 30, 2015 Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... Fourth quarter and fiscal 2015 overview: ... the fourth quarter, up 33% over last year,s comparable ... year-over-year. , Diluted EPS of $0.50 for the ...
(Date:4/30/2015)... April 30, 2015  IRIDEX Corporation (NASDAQ: IRIX ... quarter 2015 financial results after the market closes on ... the release, the Company will host a conference call ... Time on Thursday, May 7, 2015 ... business developments. Interested parties may access the ...
Breaking Medicine Technology:Cambrex Reports First Quarter 2015 Financial Results 2Cambrex Reports First Quarter 2015 Financial Results 3Cambrex Reports First Quarter 2015 Financial Results 4Cambrex Reports First Quarter 2015 Financial Results 5Cambrex Reports First Quarter 2015 Financial Results 6Cambrex Reports First Quarter 2015 Financial Results 7Cambrex Reports First Quarter 2015 Financial Results 8Cambrex Reports First Quarter 2015 Financial Results 9Cambrex Reports First Quarter 2015 Financial Results 10Cambrex Reports First Quarter 2015 Financial Results 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
... Mich. , June 14 Stryker Corporation ... of its manufacturing facilities have earned Leadership in Energy ... Building Council (USGBC).  LEED is an internationally recognized green ... a framework for identifying and implementing practical and measurable ...
... , June 14 Codexis, Inc. (Nasdaq: CDXS) ... Officer, received the Ernst & Young Entrepreneur Of The Year ® ... , , , ... Young LLP, the award recognizes outstanding entrepreneurs who are building and leading ...
Cached Medicine Technology:Stryker Facilities Earn LEED® Certifications 2Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California 2Codexis CEO Alan Shaw Named Ernst & Young Entrepreneur Of The Year® 2010 Recipient in Northern California 3
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 NuevaCare ... MnemeTherapy® at two upcoming area seminars. The first event ... PSA Annual Regional Stroke Conference to be held at ... offered on Wednesday, May 13 during the Dementia Conference ... , “These seminars offer an excellent opportunity to ...
(Date:5/3/2015)... 2015 HealthPostures, a pioneering ergonomics ... its appearance at the , May 5 - 7, ... will exhibit at the conference include its bestselling TaskMate ... solutions is the 6100 TaskMate Executive. Features of the ... adjustable keyboard tray, extended platform work surface and supply ...
(Date:5/2/2015)... BC (PRWEB) May 02, 2015 Vancouver fencing ... will now provide valuable advice to prospective clients related to ... are looking to install railings around their decks and patios. ... several questions that pop up once the person rolls up ... phases of installing a railing in finding a gate that ...
(Date:5/2/2015)... It’s a pattern that won’t relent anytime ... on this planet, cyber scammers will immediately be thinking ... their own personal gain. And on April 30, ... issued an alert titled “Nepal Earthquake Disaster Email Scams,” ... earthquake in Nepal. The scam emails may contain links ...
(Date:5/2/2015)... On Tuesday April 7th, the patient care ... celebrate improvements in patient care. In 2014 the hospital, ... zero acquired ventilator associated infections, zero central line associated ... also recently named a Top Performer by the Joint ... the teamwork of staff from all departments involved in ...
Breaking Medicine News(10 mins):Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... are planning to study the relationship between global warming ... will be funded by the U.S. Centers for Disease ... individuals have died due to the heat wave that ... track the rising temperature to these illness and deaths ...
... have seen evident improvement in the death rates of Aborigines ... benefits of improved healthcare that has brought down death rates ... of funds into healthcare will see far more results in ... and quality of life., ,The study's leader, David ...
... of graphic pictures on cigarette packets, Benson and Hedges, a ... reinventing the packaging of cigarettes in tins which carry health ... removed. , ,Action on Smoking and Health (ASH) ... for inventing ways to reduce the impact of health warnings ...
... Reports have indicated that doctors in the US U.S. ... the condition, leaving some patients to suffer for years.// ... diseases in the world, and according to the World ... million in the year 2004. A tuberculosis bacterium has ...
... FDA-approved tool to treat drug-resistant HIV thanks to a ... ,"There are many treatments for AIDS on the market, ... Arun Ghosh (pronounced A-rune GO-sh), a professor with a ... chemistry and molecular pharmacology. "This is the first treatment ...
... women with endometrial cancer should be screened for inherited ... several other cancers.// ,The study showed that ... diagnosed endometrial cancer patients have mutations for Lynch syndrome, ... cancer, or HNPCC. ,People with Lynch syndrome ...
Cached Medicine News:Health News:Doctors In US Lack Skills For The Diagnosis Of TB 2Health News:Research Leads to First Treatment for Drug-Resistant HIV 2Health News:Research Leads to First Treatment for Drug-Resistant HIV 3Health News:Research Leads to First Treatment for Drug-Resistant HIV 4Health News:Uterine Cancer May be Clue to Inherited Syndrome 2Health News:Uterine Cancer May be Clue to Inherited Syndrome 3
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
... chemistry integrated systems combine the ease of ... power of the Multiply and Quicklyte integrated ... module to meet the challenges of your ... menus, the systems can meet over 97% ...
The Embla 96/384 well washer is a top-loading, robotic-compatible plate washer for 96- and 384-well microplate washing. It is ideal for ELISAs and most cell applications....
Auto Plate Washer: 96-well washing. The ELx405 Auto Washer is the most precise and reliable washer available. Many unique features lower background absorbance values and increase the signal-to-noise ...
Medicine Products: